EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The gut–heart axis in cardio-oncology

Nicole S L Chan, Courtney Cross, Joanne Bowen, Clive Prestidge, Feargal J Ryan, Mohsen Dorraki iD, Sanuri Liyanage, Shiwani Sharma, Rajesh Pathy iD, Christina A Bursill, Peter J Psaltis, Francine Z Marques und 2 weitere

Cardiovascular Research · 2026

DOI: 10.1093/cvr/cvag146 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, 2026. Verfasst von Nicole S L Chan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Translational Nanomedicine & Biotherapeutics Group, School of Pharmacy and Biomedical Science, Adelaide University, Adelaide City West Campus, North …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Gastrointestinal Microbiome, Neoplasms, Cardiovascular Diseases. Die Arbeit nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Council SA's Beat Cancer, State Government of South Australia through the Department of Health and Wellbeing, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As cancer survival rates improve, the long-term burden of treatment has become increasingly evident. Cancer survivors face a markedly higher risk of cardiovascular-related complications and premature, non–cancer-related mortality. In particular, cardiovascular disease (CVD) is disproportionately prevalent, with survivors approximately 40% more likely to develop and die from CVD compared to the general population. Although this increased morbidity reflects both acute cardiotoxic events and the later development and progression of more chronic CVDs, traditionally viewed as direct consequences of cancer therapies, the underlying mechanisms, especially those that are feasible to modify, are poorly understood. Emerging evidence positions the gut–heart axis as a central regulator of cardiovascular risk in cardio-oncology. This avenue is especially compelling to explore as the gut microbiome is well documented to be altered by cancer therapies, including chemotherapy, immune checkpoint inhibitors, targeted therapies, and radiation, with profound and persistent changes in diversity, composition and function widely reported across clinical cohorts. Comparable microbial changes have been observed in non-cancer cohorts with cardiovascular disease. For example, specific microbial metabolites have been reported to exert cardiovascular protective benefits in hypertension. Thus, there is a compelling opportunity to explore the gut microbiome to advance our understanding and ability to prevent cardiovascular disease in cancer survivors. This review synthesizes current evidence linking the gut microbiome to cancer therapy-related cardiac dysfunction (CTRCD), evaluates microbial metabolites as predictive biomarkers of cardiotoxicity, and discusses microbiome-targeted modulation as an emerging strategy for improving cardiovascular outcomes in cancer survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsGastrointestinal MicrobiomeNeoplasmsCardiovascular DiseasesCancer SurvivorsHeartBacteriaHeart DiseasesHumansAnimalsCardiotoxicityRisk AssessmentRisk FactorsHeart Disease Risk Factors

Stichwörter der Autor:innen

CTRCDCancer therapy-related cardiac dysfunctionCardiovascular healthChemotherapy-induced cardiotoxicityImmunotherapyMicrobiotaRadiotherapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Translational Nanomedicine & Biotherapeutics Group, School of Pharmacy and Biomedical Science, Adelaide University, Adelaide City West Campus, North Terrace, Adelaide, SA 5000, Australia.
  • School of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, SA 5000, Australia.
  • Supportive Oncology Research Group, Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA 5000, Australia.
  • Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia.
  • Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA 5000, Australia.
  • School of Computer Science and Information Science, Adelaide University, Adelaide, SA 5005, Australia.

ORCID-Profile: Mohsen Dorraki, Rajesh Pathy, Paul Joyce

Förderung

  • Cancer Council SA's Beat Cancer
  • State Government of South Australia through the Department of Health and Wellbeing
  • National Health and Medical Research Council
  • University of Adelaide
  • NCRIS
  • Veronika Sacco Postdoctoral Clinical Cancer Research
  • South Australian Health and Medical Research Institute
  • National Heart Foundation of Australia

Zitieren

APA

Chan, N. S. L., Cross, C., Bowen, J., Prestidge, C., Ryan, F. J., Dorraki, M., Liyanage, S., Sharma, S., Pathy, R., Bursill, C. A., Psaltis, P. J., Marques, F. Z., Wardill, H. R., & Joyce, P. (2026). The gut–heart axis in cardio-oncology. Cardiovascular Research. https://doi.org/10.1093/cvr/cvag146

Vancouver

Chan NSL, Cross C, Bowen J, Prestidge C, Ryan FJ, Dorraki M, et al. The gut–heart axis in cardio-oncology. Cardiovascular Research. 2026. doi:10.1093/cvr/cvag146

BibTeX
@article{Chan2026,
  author = {Chan, Nicole S L and Cross, Courtney and Bowen, Joanne and Prestidge, Clive and Ryan, Feargal J and Dorraki, Mohsen and Liyanage, Sanuri and Sharma, Shiwani and Pathy, Rajesh and Bursill, Christina A and Psaltis, Peter J and Marques, Francine Z and Wardill, Hannah R and Joyce, Paul},
  title = {The gut–heart axis in cardio-oncology},
  journal = {Cardiovascular Research},
  year = {2026},
  doi = {10.1093/cvr/cvag146}
}
Kostenlos starten →